The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.
Hepatocellular Carcinoma
PROCEDURE: TAI
Overall survival (OS), overall survival, From date of randomization until the date of death from any cause, assessed up to 60 months
recurrence-free survival (RFS), recurrence-free survival, From date of randomization until the date of recurrence, assessed up to 60 months|recurrence rate, recurrence rate, 1 year, 2 year, 3 year, 5 year after surgery
To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.